Clinical Trials Resource Center

New Medical Therapies™

Cutaneous Candidiasis

January 13, 2003

Versicor reported positive results from a phase II trial investigating anidulafungin for the treatment of invasive candidiasis and candidemia. Data showed that 88 % (23/26) of subjects exhibited a global response rate with a loading dose of 200 mg followed by a 100 mg maintenance dose per day. Results also showed that 89 % (25/28) of subjects exhibited a response rate with an analogous anidulafungin regimen of 150 mg followed by 75 mg per day, and 81 % (21/26) of subjects with 100 mg followed by 50 mg. These rates compare favorably with rates reported in previous clinical trials with other agents, such as fluconazole, amphotericin B and caspofungin, which range from 56 % to 81 % in subjects with invasive candidiasis/candidemia. The drug was well tolerated and adverse events attributable to the treatment were infrequent and similar for each dose. The randomized, open-label trial enrolled approximately 120 subjects in the U.S. with invasive candidiasis/candidemia.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.